How big is Taysha Gene Therapies, Inc.?

As of Jun 18, Taysha Gene Therapies, Inc. has a market capitalization of 666.90 million and reported net sales of 7.22 million, with a net loss of 86.77 million over the latest four quarters.

As of Jun 18, Taysha Gene Therapies, Inc. has a market capitalization of 666.90 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 7.22 million for the latest four quarters, while the net profit for the same period was a loss of 86.77 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 71.53 million and total assets amounting to 276.41 million.

What does Taysha Gene Therapies, Inc. do?

Taysha Gene Therapies, Inc. develops adeno-associated virus-based gene therapies for monogenic diseases of the central nervous system. As of March 2025, it has a market cap of $666.90 million, with net sales of $2 million and a net loss of $22 million.

Overview:<BR>Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -22 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 666.90 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.31 <BR>Return on Equity: -149.22% <BR>Price to Book: 12.11<BR><BR>Contact Details:<BR>Address: 2280 Inwood Road, DALLAS TX: 75235 <BR>Tel: 1 214 6120000 <BR>Website: https://tayshagtx.com/

Should I buy, sell or hold Taysha Gene Therapies, Inc.?

Is Taysha Gene Therapies, Inc. overvalued or undervalued?

As of March 28, 2023, Taysha Gene Therapies, Inc. is rated as "risky" and overvalued, with a Price to Book Value of 13.49, an EV to EBITDA of -8.12, a negative ROE of -149.22%, and a 1-year stock return of -15.88%, significantly underperforming the S&P 500's 10.26% return.

As of 28 March 2023, Taysha Gene Therapies, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios include a Price to Book Value of 13.49, an EV to EBITDA of -8.12, and a negative ROE of -149.22%. <BR><BR>In comparison to its peers, Taysha's EV to EBITDA ratio is significantly worse than Poseida Therapeutics, Inc. at -13.33 and Verastem, Inc. at -1.91, both of which are also categorized as risky. The company's recent stock performance has been underwhelming, with a 1-year return of -15.88%, contrasting sharply with the S&P 500's 10.26% return in the same period, further indicating a challenging valuation landscape.

Is Taysha Gene Therapies, Inc. technically bullish or bearish?

As of October 3, 2025, Taysha Gene Therapies, Inc. shows a bullish technical trend with strong momentum indicators, despite a 78.31% decline over the past five years, while outperforming the S&P 500 year-to-date with a return of 155.49%.

As of 3 October 2025, the technical trend for Taysha Gene Therapies, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Additionally, the Bollinger Bands show a bullish signal on the monthly timeframe. The KST is bullish on both weekly and monthly periods, while the monthly Dow Theory is mildly bullish. <BR><BR>Despite the current bullish indicators, the stock has experienced a significant decline over the past five years, down 78.31%, contrasting sharply with the S&P 500's 100.56% gain during the same period. However, in the shorter term, Taysha has outperformed the S&P 500 with a year-to-date return of 155.49% compared to the S&P's 14.18%. Overall, the current technical stance is bullish with strong momentum indicators.